Wen Kai Weng

Wen Kai Weng

Stanford University - Stanford / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 1651140
person_outline Wen Kai Weng's MOST POPULAR ARTICLES
1-) Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphomaWK Weng, R LevyJournal of clinical oncology 21 (21), 3940-3947, 200315442003
2-) Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotypeWK Weng, D Czerwinski, J Timmerman, FJ Hsu, R LevyJournal of clinical oncology 22 (23), 4717-4724, 20042722004
3-) Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancerHE Kohrt, R Houot, K Weiskopf, MJ Goldstein, F Scheeren, D Czerwinski, ...The Journal of clinical investigation 122 (3), 1066-1075, 20122652012
4-) Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphomaWK Weng, R LevyBlood, The Journal of the American Society of Hematology 98 (5), 1352-1357, 20012672001
5-) A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphomaE Racila, BK Link, WK Weng, TE Witzig, S Ansell, MJ Maurer, J Huang, ...Clinical Cancer Research 14 (20), 6697-6703, 20081992008